The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
1d
Verywell Health on MSNA New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer TypeThe FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...
The new drug is meant to treat specific types of advanced breast cancer which are resistant to hormone therapy.
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
9d
GlobalData on MSNFDA expands Enhertu approval to include HER2-ultralow breast cancer patientsAstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
Jan. 28, 2025 – The FDA has approved a new treatment for certain types of advanced breast cancer that have spread or cannot be removed with surgery. Known as fam-trastuzumab deruxtecan but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results